Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04551963
Recruitment Status : Recruiting
First Posted : September 16, 2020
Last Update Posted : December 17, 2020
Sponsor:
Information provided by (Responsible Party):
BeiGene

Brief Summary:
The primary objective of this study is to assess the steady-state zanubrutinib pharmacokinetics (PK) when coadministered with moderate and strong cytochrome P450 A (CYP3A) inhibitors.

Condition or disease Intervention/treatment Phase
B-cell Malignancies Drug: Zanubrutinib Drug: Fluconazole Drug: Diltiazem Drug: Voriconazole Drug: Clarithromycin Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Drug-Drug Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Patients With B-Cell Malignancies
Actual Study Start Date : November 15, 2020
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Zanubrutinib + Moderate CYP3A
Cycle 1 (28 days): Zanubrutinib 80 mg twice daily (BID) + fluconazole (days 4 - 10), zanubrutinib 320 mg once daily (QD) (days 13 - 19), zanubrutinib 80 mg BID + diltiazem (days 20 - 26) Cycles 2 - 6 (28 days each): zanubrutinib 160 mg BID or 320 mg QD
Drug: Zanubrutinib
80 mg capsules administered at a dose and frequency as specified in the treatment arm
Other Names:
  • BGB-3111
  • BRUKINSA

Drug: Fluconazole
400 mg administered as 2 x 200 mg capsules once daily (QD)

Drug: Diltiazem
180 mg capsule administered once daily (QD)

Experimental: Zanubrutinib + Strong CYP3A
Cycle 1 (28 days): Zanubrutinib 80 mg QD + voriconazole (days 4 - 10), zanubrutinib 320 mg QD (days 13 - 19), zanubrutinib 80 mg QD + clarithromycin (days 20 - 26) Cycles 2 - 6 (28 days each): zanubrutinib 160 mg BID or 320 mg QD
Drug: Zanubrutinib
80 mg capsules administered at a dose and frequency as specified in the treatment arm
Other Names:
  • BGB-3111
  • BRUKINSA

Drug: Voriconazole
200 mg capsules administered twice daily (BID)

Drug: Clarithromycin
250 mg capsules administered twice daily (BID)




Primary Outcome Measures :
  1. area under plasma concentration-time curve up to the last measurable concentration (AUC0-t) [ Time Frame: Day 3, Day 10, and Day 26 of Cycle 1 (28-day cycle) ]
  2. AUC from 0 to 24 hours (AUC0-24h) [ Time Frame: Day 3, Day 10, and Day 26 of Cycle 1 (28-day cycle) ]
  3. maximum plasma concentration (Cmax) [ Time Frame: Day 3, Day 10, and Day 26 of Cycle 1 (28-day cycle) ]
  4. time to reach the Cmax (Tmax) [ Time Frame: Day 3, Day 10, and Day 26 of Cycle 1 (28-day cycle) ]
  5. apparent terminal elimination half-life (t1/2) [ Time Frame: Day 3, Day 10, and Day 26 of Cycle 1 (28-day cycle) ]

Secondary Outcome Measures :
  1. Number of participants experiencing Adverse Events (AEs) [ Time Frame: Up to 6 28-day cycles ]
  2. Number of participants experiencing Serious Adverse Events (SAEs) [ Time Frame: Up to 6 28-day cycles ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. Histologically or cytologically confirmed CLL/SLL, MCL, WM, or MZL.
  2. Relapsed or refractory disease after at least 1 prior line of systemic therapy. Participants with MZL are required to have failed an anti-CD20 monoclonal antibody-containing chemotherapy regimen.
  3. Baseline Eastern Cooperative Oncology Group performance status of 0 to 1.
  4. Meet protocol guidelines for adequate bone marrow, kidney, liver, and cardiac function.

Key Exclusion Criteria:

  1. Requirement of chronic treatment with strong and moderate CYP3A inhibitors or inducers or with drugs that are not allowed to be used in combination with diltiazem, clarithromycin, fluconazole, or voriconazole.
  2. History of stroke or intracranial hemorrhage (within 6 months of treatment start).
  3. Known hypersensitivity or contraindication to zanubrutinib, diltiazem, clarithromycin, fluconazole, or voriconazole.
  4. Prior exposure to zanubrutinib or other Bruton tyrosine kinase inhibitor
  5. Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04551963


Contacts
Layout table for location contacts
Contact: BeiGene +1-877-828-5568 clinicaltrials@beigene.com

Locations
Layout table for location information
Australia, New South Wales
Concord General Repatriation Hospital Recruiting
Concord, New South Wales, Australia, 2139
Australia, Queensland
John Flynn Private Hospital Recruiting
Tugun, Queensland, Australia, 4224
Australia, South Australia
Royal Adelaide Hospital Recruiting
Adelaide, South Australia, Australia, 5000
Flinders Medical Centre Recruiting
Bedford Park, South Australia, Australia, 5042
Australia, Victoria
Monash Health Recruiting
Clayton, Victoria, Australia, 3168
Peninsula Private Hospital Recruiting
Frankston, Victoria, Australia, 3199
Australia, Western Australia
Linear Clinical Research Recruiting
Nedlands, Western Australia, Australia, 6009
Sponsors and Collaborators
BeiGene
Investigators
Layout table for investigator information
Study Director: William Novotny, MD BeiGene
Layout table for additonal information
Responsible Party: BeiGene
ClinicalTrials.gov Identifier: NCT04551963    
Other Study ID Numbers: BGB-3111-113
First Posted: September 16, 2020    Key Record Dates
Last Update Posted: December 17, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Clarithromycin
Fluconazole
Voriconazole
Zanubrutinib
Diltiazem
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Antifungal Agents
14-alpha Demethylase Inhibitors
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 CYP2C19 Inhibitors
Antihypertensive Agents
Calcium Channel Blockers
Membrane Transport Modulators
Calcium-Regulating Hormones and Agents
Vasodilator Agents
Antineoplastic Agents
Protein Kinase Inhibitors